Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
- PMID: 28356445
- DOI: 10.1161/CIR.0000000000000484
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
Erratum in
-
Correction to: Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.Circulation. 2019 Jul 30;140(5):e181-e184. doi: 10.1161/CIR.0000000000000703. Epub 2019 Jul 29. Circulation. 2019. PMID: 31356128 No abstract available.
Abstract
Background: Kawasaki disease is an acute vasculitis of childhood that leads to coronary artery aneurysms in ≈25% of untreated cases. It has been reported worldwide and is the leading cause of acquired heart disease in children in developed countries.
Methods and results: To revise the previous American Heart Association guidelines, a multidisciplinary writing group of experts was convened to review and appraise available evidence and practice-based opinion, as well as to provide updated recommendations for diagnosis, treatment of the acute illness, and long-term management. Although the cause remains unknown, discussion sections highlight new insights into the epidemiology, genetics, pathogenesis, pathology, natural history, and long-term outcomes. Prompt diagnosis is essential, and an updated algorithm defines supplemental information to be used to assist the diagnosis when classic clinical criteria are incomplete. Although intravenous immune globulin is the mainstay of initial treatment, the role for additional primary therapy in selected patients is discussed. Approximately 10% to 20% of patients do not respond to initial intravenous immune globulin, and recommendations for additional therapies are provided. Careful initial management of evolving coronary artery abnormalities is essential, necessitating an increased frequency of assessments and escalation of thromboprophylaxis. Risk stratification for long-term management is based primarily on maximal coronary artery luminal dimensions, normalized as Z scores, and is calibrated to both past and current involvement. Patients with aneurysms require life-long and uninterrupted cardiology follow-up.
Conclusions: These recommendations provide updated and best evidence-based guidance to healthcare providers who diagnose and manage Kawasaki disease, but clinical decision making should be individualized to specific patient circumstances.
Keywords: AHA Scientific Statements; Kawasaki syndrome; aneurysm; arteritis; coronary vessels; immunoglobulins, intravenous; thrombosis; vasculitis.
© 2017 American Heart Association, Inc.
Conflict of interest statement
The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.
Similar articles
-
Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.Pediatrics. 2004 Dec;114(6):1708-33. doi: 10.1542/peds.2004-2182. Pediatrics. 2004. PMID: 15574639
-
Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.Circulation. 2004 Oct 26;110(17):2747-71. doi: 10.1161/01.CIR.0000145143.19711.78. Circulation. 2004. PMID: 15505111
-
Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association.Circulation. 2024 Dec 3;150(23):e481-e500. doi: 10.1161/CIR.0000000000001295. Epub 2024 Nov 13. Circulation. 2024. PMID: 39534969 Review.
-
[National consensus on the cardiological treatment and follow-up of Kawasaki disease].An Pediatr (Engl Ed). 2018 Sep;89(3):188.e1-188.e22. doi: 10.1016/j.anpedi.2018.04.003. Epub 2018 May 16. An Pediatr (Engl Ed). 2018. PMID: 29778491 Spanish.
-
Management of Kawasaki disease in adults.Heart. 2017 Nov;103(22):1760-1769. doi: 10.1136/heartjnl-2017-311774. Epub 2017 Jul 27. Heart. 2017. PMID: 28751537 Review.
Cited by
-
Characteristics of immune function in the acute phase of Henoch-Schönlein purpura.Clin Rheumatol. 2021 Sep;40(9):3711-3716. doi: 10.1007/s10067-021-05707-6. Epub 2021 Mar 29. Clin Rheumatol. 2021. PMID: 33782751
-
Correct identification of incomplete Kawasaki disease.J Int Med Res. 2021 Mar;49(3):3000605211001712. doi: 10.1177/03000605211001712. J Int Med Res. 2021. PMID: 33784852 Free PMC article. Review.
-
The Anti-inflammatory Effect of Soluble Epoxide Hydrolase Inhibitor and 14, 15-EET in Kawasaki Disease Through PPARγ/STAT1 Signaling Pathway.Front Pediatr. 2020 Aug 12;8:451. doi: 10.3389/fped.2020.00451. eCollection 2020. Front Pediatr. 2020. PMID: 32903307 Free PMC article.
-
FCGR2/3 polymorphisms are associated with susceptibility to Kawasaki disease but do not predict intravenous immunoglobulin resistance and coronary artery aneurysms.Front Immunol. 2024 Sep 18;15:1323171. doi: 10.3389/fimmu.2024.1323171. eCollection 2024. Front Immunol. 2024. PMID: 39359734 Free PMC article.
-
Kawasaki Disease and Clinical Outcome Disparities Among Black Children.J Pediatr. 2021 Feb;229:54-60.e2. doi: 10.1016/j.jpeds.2020.09.052. Epub 2020 Sep 24. J Pediatr. 2021. PMID: 32980379 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous